ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.04−0.06 (-5.45%)
Close on Nov 18, 2026Market cap $314.42MP/E –Yield –
ProKidney free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ProKidney's free cash flow for the twelve months ending Jun 30, 2026 was -$159.73M. For fiscal 2025 it was -$135.31M. The highest annual figure on record is -$30.64M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.31M | – |
| FY2024 | Dec 31, 2024 | -$155.86M | – |
| FY2023 | Dec 31, 2023 | -$124.27M | – |
| FY2022 | Dec 31, 2022 | -$78.94M | – |
| FY2021 | Dec 31, 2021 | -$55.49M | – |
| FY2020 | Dec 31, 2020 | -$30.64M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$35.61M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.53M | – |
See a number that looks wrong?